# Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

> clinical trial · VERIFIED · 2026-07-13

Status: RECRUITING · Sponsor: Nuvalent Inc. · Condition: Non-small Cell Lung Cancer

- Company: Nuvalent Inc.
- Sector: Non-small Cell Lung Cancer
- Primary source: https://clinicaltrials.gov/study/NCT06765109

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.